Is Arcturus Therapeutics Holdings Inc. (ARCT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 14.1% / 30% | 117.3% / 30% | 2.0% / 30% | 10.98% / 5% | ✗ NOT HALAL |
| DJIM | 14.1% / 33% | 117.3% / 33% | 2.0% / 33% | 10.98% / 5% | ✗ NOT HALAL |
| MSCI | 8.3% / 33% | 68.9% / 33% | 1.2% / 33% | 10.98% / 5% | ✗ NOT HALAL |
| S&P | 14.1% / 33% | 117.3% / 33% | 2.0% / 33% | 10.98% / 5% | ✗ NOT HALAL |
| FTSE | 8.3% / 33% | 68.9% / 33% | 1.2% / 50% | 10.98% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -36.8% | |
| Operating Margin | -435.1% | |
| Net Margin | -80.2% | |
| Return on Equity (ROE) | -28.9% | |
| Return on Assets (ROA) | -15.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$74M |
| Free Cash Flow | -$75M |
| Total Debt | $25M |
| Debt-to-Equity | 11.7 |
| Current Ratio | 6.6 |
| Total Assets | $271M |
Price & Trading
| Last Close | $7.08 |
| 50-Day MA | $7.36 |
| 200-Day MA | $11.59 |
| Avg Volume | 490K |
| Beta | 2.5 |
|
52-Week Range
$5.85
| |
About Arcturus Therapeutics Holdings Inc. (ARCT)
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Arcturus Therapeutics Holdings Inc. (ARCT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Arcturus Therapeutics Holdings Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Arcturus Therapeutics Holdings Inc.'s debt ratio?
Arcturus Therapeutics Holdings Inc.'s debt ratio is 14.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 8.3%.
What are Arcturus Therapeutics Holdings Inc.'s key financial metrics?
Arcturus Therapeutics Holdings Inc. has a market capitalization of $192M, and revenue of $67M. The company maintains a gross margin of -36.8% and a net margin of -80.2%. Return on equity stands at -28.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.